

Breaking down causes, consequences, and mediating effects of age-related telomere shortening on human health

Samuel Moix^{1,2,*}, Marie Sadler^{1,2,3}, Zoltán Kutalik^{1,2,3,+,*}, and Chiara Auwerx^{1,2,3,4,+,*}

¹Department of Computational Biology, UNIL, Lausanne 1015, Switzerland

²Swiss Institute of Bioinformatics, Lausanne 1015, Switzerland

³University Center for Primary Care and Public Health, Lausanne 1015, Switzerland

⁴Center for Integrative Genetics, UNIL, Lausanne 1015, Switzerland

*These authors jointly supervised this work

*Corresponding authors

January 11, 2024

Abstract

Telomeres represent repeated DNA sequences at the ends of chromosomes, which shorten with each cell division. Factors modulating telomere attrition and the health consequences thereof are not fully understood. To address this, we leveraged data from 326,363 unrelated UK Biobank participants of European ancestry and used linear regression and bidirectional univariable and multivariable Mendelian randomization (MR and MVMR) to elucidate the relationships between leukocyte telomere length (LTL) and 141 complex traits, including diseases, biomarkers, and lifestyle factors. We confirm that telomeres shorten with age and show a stronger decline in males than in females, which cannot be explained by hormonal or lifestyle differences. MR revealed 23 traits modulating LTL; e.g., smoking cessation and high educational attainment associated with longer LTL, while weekly alcohol intake, body mass index, urate levels, and female reproductive events, such as childbirth, associated with shorter LTL. We also identified 26 traits affected by LTL, with risk for cardiovascular, pulmonary, renal, and some autoimmune diseases being increased by short LTL, while longer LTL increased risk for other autoimmune conditions and cancers. Through MVMR, we show that LTL partially mediates the impact of educational attainment, body mass index, and female age at childbirth on lifespan. These results provide new insights into the biology of telomere regulation by shedding light on the modulators, consequences, and the mediatory role of telomere shortening, portraying an intricate relationship between LTL, diseases, lifestyle, and socio-economic factors.

Keywords— Telomeres; Mendelian randomization; UK Biobank; lifespan; complex traits; aging; lifestyle; female reproduction; sex-differences

1 Introduction

2 Aging represents a leading risk factor for diseases such as cancer, cardiovascular diseases, and neurodegenera-
3 tion [1]. Chronological age fails to account for individual differences in aging rates and vulnerability to diseases [2].
4 Biological age intends to address this limitation by reflecting the physiological state of an individual and accounting
5 for variations in cellular and tissue health. Several biomarkers can be used to estimate biological age, with DNA
6 methylation being particularly popular due to its availability across tissues, and its sensitivity to both disease states
7 and environmental factors [3, 4, 5]. However, given the complex nature of the aging process, additional biomarkers
8 beyond DNA methylation are required to fully understand the underlying causes and mechanisms of aging and
9 age-related diseases [6].

10

11 One such biomarker is telomere length. Telomeres are DNA repeats at chromosome ends that act as protec-
12 tive caps against genomic degradation. As organisms age, they undergo an increasing number of cell divisions,
13 leading to an incremental decrease in telomere length. Acting as mitotic clocks, telomeres shorten until they reach
14 a critical length, triggering cellular senescence and/or apoptosis [7]. Consequently, shorter telomeres have been
15 associated with lifestyle factors, including smoking [8], reduced physical activity [9], high processed meat and low
16 fruit consumption [10, 11], as well as a wide range of diseases, from pulmonary [12], renal [13], and metabolic [14]
17 disorders to cancer [15, 16]. Paradoxically, longer telomeres have also been associated with poor health outcomes,
18 especially cancers [17]. However, most studies so far were limited in the number of studied traits, relied on small
19 sample sizes, and did not probe the directionality of the established associations.

20

21 Recently, efforts to assess leukocyte telomere length (LTL) in large population biobanks have allowed compre-
22 hensive exploration of its relationships with lifestyle factors and health outcomes. Performing an LTL phenome-wide
23 association study in 62,271 participants from the Vanderbilt University and Marshfield Clinic biobanks, Allaire *et*
24 *al.*, identified associations with 67 phenotypes and showed that both shorter and longer telomeres associated with
25 increased mortality [18]. Release of LTL measurements for ~500,000 UK Biobank (UKBB) participants [19] and the
26 companion first large-scale telomere length genome-wide association study (GWAS) [20] prompted investigation of
27 the impact of LTL on hundreds of traits using phenome-wide Mendelian randomization (MR) [20, 21]. These studies
28 showed that longer LTL increases risk for neoplastic and genitourinary diseases while lowering risk for respira-
29 tory, digestive, and cardiovascular disorders [20, 21], with about 40% of these associations confirmed when using
30 FinnGen disease association summary statistics [21].

31

32 Our study builds on this body of work by dissecting observational correlations between LTL and 141 traits into
 33 causes and consequences through a bidirectional MR causal framework (Figure 1). Additionally, we performed sex-
 34 stratified analyses and used multivariable Mendelian Randomization (MVMR) to disentangle the interplay between
 35 LTL and various traits, with a particular focus on the mediating role of LTL in longevity. Together, we identify traits
 36 influencing LTL, and how in turn the latter impacts the human phenome, contributing to a deeper understanding of
 37 telomere biology and its relation to health.




Figure 1. Schematic representation of the study's workflow.

Red and light green boxes denote steps using individual-level phenotypic data from the UK Biobank and GWAS summary statistics, respectively. Top: Data extraction process. Middle: Analyses focused on LTL trait relationships including observational correlation (β ; black), Mendelian randomization to assess the impact of LTL on traits ($\alpha_{LTL \rightarrow T}$; red), and Mendelian randomization to assess the impact of traits on LTL ($\alpha_{T \rightarrow LTL}$; blue). LTL covariates comprise age, age^2 , array, sex, and the interaction of the latter with the priors. U = unmeasured confounding factors; IVs = instrumental variables (i.e., genetic variants with genome-wide significant association to the considered trait). SNP = single nucleotide polymorphism. Bottom: Follow-up analyses including sex-specific LTL effects and LTL mediation analysis through multivariable Mendelian randomization.

38 **Materials and methods**

39 **Data**

40 Individual-level UK Biobank data

41 Observational analyses were carried out in the UK Biobank (UKBB), a cohort of ~500,000 volunteers from the
42 general UK population aged between 40–69 years at recruitment [22]. Phenotype data were accessed through ap-
43 proved application 16389. Analyses were conducted on 326,363 participants with known sex, age, and LTL after the
44 exclusion of individuals of non-white and non-British ancestry (self-reported + genetically defined), relatives ($\leq 3^{rd}$
45 degree), and gender mismatches (see UKBB Resource 531), as well as those who retracted their participation.
46 Given that LTL measurements are derived from blood, we further excluded 4,376 individuals with blood malignan-
47 cies, based on self-reports (UKBB field #20001 codes 1047, 1048, 1050, 1051, 1052, 1053, 1055, 1056, 1058) or
48 hospital diagnoses (#41270; International Classification of Diseases 10th Revision [ICD10] codes mapping to the
49 PheCode "cancer of lymphatic and hematopoietic tissue" [23]).

50

51 We used technically adjusted and standardized LTL (#22192) [19] and assessed its relation to 166 complex
52 traits (Table S1). These include 60 common diseases defined based on hospital diagnoses (#41270; last diag-
53 nosis September 2021), while excluding from controls individuals with self-reported (#20001, #20002) or hospital-
54 diagnosed (#41270) conditions related to the investigated disease [24]. Disease phenotypes were used to calculate
55 a disease burden phenotype, i.e., the total number of diseases diagnosed in an individual among the 60 considered
56 ones. The remaining 105 traits include 11 anthropometric traits (e.g., weight), 41 biomarkers (e.g., serum lipids),
57 18 life events (e.g., age at menarche and menopause), 26 lifestyles (e.g., beef intake) and socio-economic factors
58 (e.g., Townsend deprivation index), and 9 miscellaneous traits. Definitions of composite phenotypes are described
59 in the Supplementary Note. Briefly, continuous traits with multiple instances were averaged, while the first instance
60 was used for integers or factors. To minimize noise, outliers (mean \pm 5 standard deviations [SD]) in continuous traits
61 were removed. Factorial variables were numerically converted for efficient integration into the regression model. All
62 traits, including binary predictors, were then scaled to have zero mean and unit variance to obtain more comparable
63 effect sizes. As the 167 assessed traits (i.e., 166 above-mentioned + blood cancer) were partially correlated we
64 estimated the number of effective tests [25], i.e., the number of tests needed to explain 99.5% of the variance in
65 our phenotypic dataset, to 141, resulting in a significance threshold of $p < 0.05/141 = 3.5e-4$ for observational
66 correlation and MR analyses.

67 GWAS summary statistics

When available (i.e., for non-composite traits), genome-wide association study (GWAS) summary statistics originate from the Neale group (file release July 2018; <http://www.nealelab.is/uk-biobank>) (Table S2). Summary statistics for reproductive lifespan were derived from GWAS on age at menopause and menarche by first back-transforming the effects on year-scale and then computing their difference:

$$\beta = SD_{menopause} \times \beta_{menopause} - SD_{menarche} \times \beta_{menarche}$$
$$SE = \sqrt{SD_{menopause}^2 \times SE_{menopause}^2 + SD_{menarche}^2 \times SE_{menarche}^2}$$

68 The sample size for the resulting summary statistic was set to the lowest of the two (i.e., age at menopause;
69 $N = 111,593$) and p-values were computed with a two-sided test based on a t-statistic obtained by dividing the
70 effect size by its standard error. For diseases, a set of previously compiled GWAS summary statistics [26] of pre-
71 dominantly European-descent consortia meta-analyses was used (Table S2). Summary statistics were harmonized
72 with the UK10K reference panel [27] and restricted to autosomal chromosomes. After excluding palindromic single-
73 nucleotide polymorphisms (SNP) and adjusting strand-flipped SNPs, effect sizes were standardized to represent
74 the square root of the explained variance [28].

75 Observational correlation

76 Predictors of LTL variability

77 To estimate the fraction of LTL variability explained by the human phenome, we used Lasso regression (glmnet
78 package in R [29]) with unadjusted normalized LTL as the outcome variable and traits with less than 5%, 7%, and
79 10% missing data as possible predictors in a joint model. Given the non-deterministic choice of the optimized
80 regularisation parameter (one SE rule lambda), 50 regressions were fitted and traits that were selected in at least
81 95% of the cases were considered as predictors.

82 Single trait linear regression

83 We adjusted LTL for age, age², genotyping array, sex, and the interaction of the latter with the priors and used
84 this variable as the outcome in 166 linear regression models with the traits described in Table S1 as explanatory
85 variables. Effect sizes reported in text are in SD_{LTL}/SD_{Trait} , except for the effect of age, in which case effects
86 are reported in $SD_{LTL}/year$. We followed up on specific associations with sensitivity analyses to identify possible

87 confounders:

- 88 • In individuals using cholesterol-lowering drugs (#6177 and #6153), serum lipids levels were corrected for
89 the average simvastatin effect, i.e., + 1.6 mmol/L, 1.4 mmol/L, 0.4 mmol/L, -0.1 mmol/L of total cholesterol,
90 low-density lipoprotein (LDL), triglycerides and high-density lipoprotein (HDL), respectively [30].
- 91 • Reproductive traits showing significant ($p < 0.05/141$) association with LTL were corrected for socioeconomic
92 status (SES; i.e., Townsend deprivation index (TDI; #189), average total household income before tax (#738),
93 and educational attainment (EA; see [Supplementary Note](#))).
- 94 • In addition to age, sex, and array, LTL was corrected for eosinophil (#30150), lymphocyte (#30120), monocyte
95 (#30130), neutrophil (#30140), platelet (#30080), red blood cell (#30010), reticulocyte (#30250), and white
96 blood cell (#30000) counts and linear regressions with non-blood trait count traits were performed anew to
97 ensure the LTL associations were unbiased. As a result, the available sample size reduced to $N = 308,346$.

98 Sex-stratified analysis

99 Sex-stratified linear regression of LTL on age was assessed, as well as of LTL corrected for age, age², and genotyp-
100 ing array on non-sex-specific traits. Sex-specific differences were identified by comparing male and female effects
101 and deemed strictly significant at $p < 0.05/141$ and nominally significant at $p < 0.05$ (see [Effect size compari-](#)
102 [son](#)). We investigated the possible impact of sex hormone levels (i.e., sex hormone-binding globulin (SHBG) and
103 testosterone), as well as lifestyle factors (i.e., fruit (#1309), vegetable (#1289), beef (#1369), alcohol intake fre-
104 quency (#1558), smoking status (#20116) and weekly alcohol intake (see [Supplementary Note](#))) on sex differences
105 in age-dependent telomere shortening by controlling for these factors in our regression models.

106 Female reproductive phases

107 To assess the impact of childbearing and menopause on LTL, we identified three distinct female reproductive
108 phases: (1) years before first childbirth, (2) premenopausal years after first childbirth, and (3) postmenopausal
109 years. Number of years spent in each phase was derived from current age (#21003), age at first childbirth (#2754),
110 and age at menopause onset (#3581). Phases (2) and (3) were set to 0 for females with no children (#2734: num-
111 ber of births = 0) and premenopausal women, respectively. The joint linear regression model included time spent
112 in each phase and two indicator variables for whether the women carried a pregnancy to term and experienced
113 menopause. Female participants who had their first child post-menopause, lacked a menopausal status (#2724)
114 or age at menopause (#3581), or did not specify childbirth events (#2734) or age at first childbirth (#2754) were

115 excluded from this analysis.

116 Mendelian randomization

117 Bidirectional univariable Mendelian randomization

118 GWAS summary statistics were used to conduct bidirectional two-sample Mendelian randomization (MR), with
119 $\alpha_{LTL \rightarrow T}$ representing the causal impact of LTL (exposure) on complex traits (outcome) and $\alpha_{T \rightarrow LTL}$ the causal
120 impact of complex traits (exposure) on LTL (outcome) (Figure 1). Harmonized SNPs significantly associated
121 ($p < 5e-8$) with the exposure were clumped ($p1 = 0.0001$, $p2 = 0.01$, $kb = 250$, and $r2 = 0.01$) with PLINK v1.9 [31]
122 and retained as instrumental variables (IVs). As the *HBB* gene was used as a control for the LTL measurements
123 [20], we removed the single SNP (rs1609812, $p = 3.9e-65$) associated with this gene (chr11:5'246'696-5'248'301;
124 GRCh37/hg19) to prevent spurious associations. Due to the complex long-range linkage disequilibrium (LD) struc-
125 ture of the HLA locus, 30 SNPs found on the extended HLA region (chr6:25'000'000-37'000'000; GRCh37/hg19)
126 were also removed from our IVs [32]. Further IVs were removed based on exposure-outcome harmonization, differ-
127 ence in allele frequency (≥ 0.05), and Steiger filtering ($Z \leq -1.96$). Bidirectional MR analyses were carried out with
128 the TwoSampleMR R package (v0.5.6) [33], primarily through the inverse variance weighted (IVW) method. LTL on
129 trait and trait on LTL MR effects were computed for 151 and 141 traits, respectively, with at least two IVs.

130

131 Sensitivity analyses were conducted using additional MR methods, i.e., MR Egger, simple mode, weighted
132 median, and weighted mode, to ensure robustness of the results. LTL on trait and trait on LTL MR analyses with
133 these methods were carried out for 151 and 134 traits with at least three IVs, respectively. Heterogeneity was
134 assessed using Cochran's Q-statistics. Given a high proportion of elevated Q-statistics, we additionally run MR-
135 PRESSO [34] for relationships with significant IVW MR effects. To further ensure that our results are not biased by
136 pleiotropy - which violates the MR assumption that IVs only affect the outcome through the exposure [35] - we first
137 filtered genome-wide significant exposure SNPs and harmonized these SNPs across all 152 traits with available
138 GWAS summary statistics (i.e., 151 traits + LTL). Harmonized GWAS data were clumped. We next applied Steiger
139 filtering between the exposure and all other traits to ensure that the selected SNPs are more strongly associated
140 with the exposure than with any of the other included traits. SNPs that passed filtering for all traits were retained as
141 IVs and MR analyses were conducted on these. This approach serves as a reasonable pleiotropy filter due to the
142 diverse nature of our phenotypes.

143 LTL mediation analysis

144 Excluding hematological traits due to potential confounding, we used multivariable MR (MVMR) to assess the medi-
145 ating role of LTL between 18 LTL-associated traits ($p < 0.05/141$) and lifespan (proxied from parental lifespan [36]).
146 We further examined the global mediatory role of LTL between these 18 LTL-affecting traits and 19 traits causally im-
147 pacted by LTL ($p < 0.05/141$). This corresponded to 359 pairs (18 * 20 (i.e., 19 traits + lifespan), excluding one pair
148 as insulin-like growth factor 1 (IGF-1) associated with LTL as both exposure and outcome), setting the significance
149 threshold for the total and indirect effects at $p < 0.05/359 = 1.4e-4$. During SNP harmonization, exposure IVs (i.e.,
150 trait IVs) were prioritized over mediator IVs (i.e., LTL IVs). Steiger filtering was applied to both exposure IVs with
151 respect to outcome and mediator and to mediator IVs in relation to the outcome. Indirect effects were determined
152 through two strategies: difference in coefficients and product of coefficients [37]. The former subtracts the direct
153 effect (MVMR) from the total effect (IVW), while the latter multiplies the univariable MR estimates from the exposure
154 on the mediator by the MVMR effect of the mediator on the outcome. Both approaches generated consistent results
155 and we present the product of coefficients method due to easier interpretability in the main text. We further cor-
156 rected these estimates for regression dilution bias [28]. Mediation proportions (P_M) represent the ratio of the indirect
157 ($\alpha_{indirect}$) to total (α_{total}) effect with 95% confidence intervals (upper limit capped at 100%) estimated from the 2.5th
158 and 97.5th quantiles of the distribution of 10,000 simulated ratios drawn from $\tilde{\alpha}_{indirect} \sim N(\hat{\alpha}_{indirect}, \hat{SE}(\hat{\alpha}_{indirect}))$ and
159 $\tilde{\alpha}_{total} \sim N(\hat{\alpha}_{total}, \hat{SE}(\hat{\alpha}_{total}))$.

160 Multi-trait analysis for direct effect estimation

161 For MVMR with multiple exposures and no predefined mediator, IVs were selected through a two-step process
162 [38]. First, SNPs for each exposure were ranked according to their p-values (more significant p-values receiving
163 lower ranks) and minimum rank across all exposures was determined for each SNP. This minimum rank was used
164 to prioritize SNPs in a subsequent clumping process. IVs were filtered as previously described. Finally, MVMR
165 regression estimates were compared to univariable MR estimates (see [Effect size comparison](#)). For the univariable
166 MR, we either used the same IVs as in the MVMR or employed a subset of IVs, which were retained after Steiger
167 filtering between both the outcome and the exposure of interest, as well as between the exposure of interest and
168 the other exposures. We report weak instrument bias via conditional F-statistics [39] and heterogeneity through
169 Cochran's Q-statistic [40] (see [Table S3](#)).

170 **Effect size comparison**

171 Significant differences between two estimated effect sizes $\hat{\beta}_X$ and $\hat{\beta}_Y$ were assessed with a two-sided p-value (p_{diff})

172 derived from:

$$t = \frac{\hat{\beta}_X - \hat{\beta}_Y}{\sqrt{SE_X^2 + SE_Y^2}}$$

173 which assumes that the two estimates are uncorrelated. Often these estimates have a positive correlation (as esti-

174 mated from the same data) and hence the t -statistic has a variance smaller than one, thus the test is conservative.

175 This approach was used throughout the study to assess the effect of sensitivity analyses, compare sex-specific

176 regression estimates, and compare univariable MR and MVMR results.

177 Results

178 Age and sex are the main predictors of LTL variability

179 Consistent with previous research [41], LTL significantly associated with both age ($\beta = -0.023$; $p < 2.2e-308$) and
 180 sex ($\beta = 0.091$; $p < 2.2e-308$), with a stronger ($p_{diff.} = 1.4e-25$) decline in males ($\beta_{males} = -0.025$) than in females
 181 ($\beta_{females} = -0.021$) (Figure S1). To further explore factors contributing to LTL variability, we included 80 traits (Table
 182 S1) with $< 7\%$ missingness rates as predictor variables in a Lasso regression model. Traits retained included age,
 183 sex, educational attainment (EA), waist-to-hip ratio (WHR), insulin-like growth factor 1 (IGF-1), urate, and cystatin
 184 C levels, along with four blood parameters (Table 1). Among these, LTL was found to be positively associated with
 185 female sex, higher EA, and higher IGF-1 levels, while it negatively correlated with the remaining traits. Age and
 186 sex accounted for 4.33% of the observed variance in LTL. Incorporating the nine additional above-mentioned traits
 187 increased the explained variance to 5.39%. Repeating the analysis with missingness rate thresholds of 5% and 10%
 188 retained twelve and seven traits in addition to age and sex, which together explain 5.42% and 5.36% of variability in
 189 LTL, respectively, confirming the limited predictive power of the phenome over LTL variability.

Table 1. Main determinants of leukocyte telomere length.

Effect sizes with 95% confidence intervals from a joint linear regression model for traits with less than 7% missing data retained as significant LTL predictors by lasso analysis. EA = educational attainment; IGF-1 = insulin-like growth factor 1; WHR = waist-to-hip ratio; MCH = mean corpuscular hemoglobin.

Trait	Estimate	Lower 95% CI	Upper 95% CI	P-value
Female	0.071	0.066	0.077	2.33×10^{-160}
EA	0.042	0.038	0.046	1.95×10^{-111}
IGF-1	0.028	0.024	0.032	3.57×10^{-49}
WHR	-0.002	-0.007	0.004	5.43×10^{-1}
Urate	-0.009	-0.014	-0.004	1.16×10^{-4}
Monocyte count	-0.017	-0.021	-0.013	4.89×10^{-17}
Eosinophil count	-0.021	-0.025	-0.017	1.00×10^{-28}
Cystatin C	-0.026	-0.030	-0.022	4.93×10^{-33}
Lymphocyte count	-0.039	-0.043	-0.035	7.43×10^{-87}
MCH	-0.058	-0.062	-0.055	4.98×10^{-223}
Age	-0.155	-0.159	-0.151	$< 2.2 \times 10^{-308}$

190 LTL broadly associates with complex traits

191 Age and sex being the major determinants of LTL, we adjusted LTL for age, age², genotyping array, sex, and the
 192 interaction of the latter with the priors and regressed adjusted LTL on 166 traits through linear regression, identifying
 193 100 significant associations ($p < 0.05/141$; Table S4). We observed a negative association between the disease
 194 burden and LTL ($\beta = -0.027$; $p = 1.2e-52$), suggesting that LTL acts as a global health indicator. The largest effect
 195 sizes were noted for father's ($\beta = 0.094$; $p = 4.4e-144$) and mother's ($\beta = 0.088$; $p = 8.5e-216$) age at birth, which

196 positively associated with LTL (Figure 2a). In jointly modeling LTL as a function of both parental ages at birth and the
197 participant's age, sex, their interaction, and EA, we found that the observed associations were independent of the
198 participant's education level (Figure S2). Participant's education level likely echoes parental EA [42] and indirectly
199 affects parental age at birth, indicating that the association is likely not confounded by socio-economic factors and
200 genuinely driven by older parental age at birth. Next, for the 141 traits with available GWAS summary statistics
201 and at least two IVs, we inferred bidirectional causal relationships through univariable MR, identifying 23 significant
202 causal effects of traits on LTL ($\alpha_{T \rightarrow LTL}$) and 26 significant effects of LTL on traits ($\alpha_{LTL \rightarrow T}$) ($p < 0.05/141$; Fig-
203 ure 2; Table S4). As a sensitivity analysis, we re-analyzed IVW-significant relations with MR Egger, simple mode,
204 weighted median, weighted mode, and MR-PRESSO (Figures S3-4). Furthermore, we ran IVW MR with a restricted
205 set of IVs stringently selected to minimize the pleiotropy assumption violation (see Methods; Figure S5).

206

207 Modulators of LTL

208 Lifestyle and environmental factors

209 Our results are overall concordant with deleterious lifestyle habits leading to shorter LTL (Figure 2b). A negative
210 correlation was observed between smoking cessation and LTL ($\beta = -0.039$; $p = 9.4e-50$), mirrored by a detrimental
211 causal effect of failure to quit smoking on LTL ($\alpha_{T \rightarrow LTL} = -0.142$; $p = 1.8e-4$). Alcohol consumption, measured as
212 total weekly intake of alcohol units, also exhibited a negative causal effect on LTL ($\alpha_{T \rightarrow LTL} = -0.086$; $p = 1.3e-4$),
213 while beef consumption showed a mere associative ($\beta = -0.012$; $p = 2.4e-11$) but no causal link ($p = 0.223$).
214 Conversely, healthy habits such as high fresh fruit intake ($\beta = 0.014$; $p = 6.4e-15$) and physical activity ($\beta =$
215 0.007 ; $p = 1.7e-4$) displayed positive associations with LTL, as did SES captured by average household income
216 ($\beta = 0.025$; $p = 1.1e-40$) or EA ($\beta = 0.047$; $p = 1.9e-155$), even though only the latter showed clear causal
217 evidence ($\alpha_{T \rightarrow LTL} = 0.075$; $p = 2.2e-15$). Our data also suggest that the psychological state of an individual can
218 impact LTL as depression causes shorter LTL ($\alpha_{T \rightarrow LTL} = -0.112$; $p = 4.4e-6$). One possible explanation for this
219 observation is that depression promotes oxidative stress and inflammation, both of which are critical modulators of
220 LTL [7, 43, 44]. The latter is supported by a negative causal effect of the inflammation marker C-reactive Protein
221 (CRP) on LTL ($\alpha_{T \rightarrow LTL} = -0.037$; $p = 9.3e-10$). Overall, these results highlight the significant impact of lifestyle
222 and environmental factors on LTL and support the paradigm that exposures typically considered as deleterious lead
223 to shorter LTL.




Figure 2. Observational and causal associations between traits and LTL.

Estimates (x-axis) with 95% confidence intervals (CI) for traits (y-axis) with at least one strictly significant ($p < 0.05/141$) association with LTL across the observational correlation (linear regression; β ; black) and inverse weighted-variance (IVW) Mendelian randomization (MR) estimates of LTL on trait (α ; red) and trait on LTL (α ; blue) are shown. Strictly significant effects are shown as full circles; otherwise as empty circles. For diseases (*), one SD change in LTL corresponds to one $\log(OR)$ change, implying a scale of $SD_{LTL} / \log(OR)$ for the effects of diseases on LTL, and $\log(OR) / SD_{LTL}$ for the effect of LTL on the disease, so that observational effects and MR effects are not directly comparable (see [Table S4](#)).

224 Anthropometric traits

225 We detect several associations with anthropometric traits ([Figure 2c](#)). Body metrics such as body mass index

226 (BMI) and body fat mass (BFM) demonstrated significant negative observational correlation (BMI: $\beta = -0.032$; $p =$

227 $2.4e-75$; BFM: $\beta = -0.029$; $p = 1.2e-60$) and causal effects on LTL (BMI: $\alpha_{T \rightarrow LTL} = -0.048$; $p = 4.9e-10$;
228 BFM: $\alpha_{T \rightarrow LTL} = -0.050$; $p = 7.6e-9$). Conversely, a positive correlation was observed between LTL and height
229 ($\beta = 0.018$; $p = 2.2e-24$), with MR analysis revealing a nominally significant effect of LTL on height ($\alpha_{LTL \rightarrow T} =$
230 0.062 ; $p = 4.5e-4$) and strictly significant effect of height on LTL ($\alpha_{T \rightarrow LTL} = 0.014$; $p = 4.0e-5$).

231 Female reproductive traits

232 Observational correlation between LTL and female reproductive traits including age at first (AFB; $\beta = 0.042$; $p =$
233 $1.4e-54$) and last (ALB; $\beta = 0.034$; $p = 2.5e-36$) birth, reproductive lifespan ($\beta = 0.023$; $p = 3.7e-13$), age at
234 menopause ($\beta = 0.026$; $p = 1.5e-16$), and menstrual disorders ($\beta = 0.011$; $p = 1.7e-5$) were observed (Figure 2d).
235 Only the effect of AFB ($p_{diff.} = 8.0e-10$) and ALB ($p_{diff.} = 0.001$) were significantly reduced after accounting for
236 SES, even though they remained significant (Figure S7a). Both traits also causally influenced LTL (AFB: $\alpha_{T \rightarrow LTL} =$
237 0.167 ; $p = 1.2e-5$; ALB: $\alpha_{T \rightarrow LTL} = 0.272$; $p = 6.1e-6$), suggesting that timing of female reproductive events
238 could modulate LTL. To explore this, we compared LTL in women with and without children, finding shorter LTL in
239 women who had given birth (Welch two-sample t-test: $p = 7.4e-11$), suggesting that childbirth could accelerate
240 LTL shortening. We next divided female participants' age into three reproductive periods: (1) premenopausal before
241 childbirth, (2) premenopausal after childbirth, and (3) postmenopausal, and used the number of years spent in each
242 period as predictors for LTL. LTL shortening accelerated over the course of these periods, with the weakest effect
243 on LTL found for premenopausal years before childbirth ($\beta = -0.013$; $p = 3.6e-120$), followed by premenopausal
244 years after childbirth ($\beta = -0.020$; $p = 7.1e-233$), and postmenopausal years ($\beta = -0.024$; $p < 2.2e-308$) (Figure
245 3), in line with the hypothesis that female reproductive events trigger acceleration in LTL shortening.




Figure 3. Schematic representation of LTL shortening across different female reproductive life phases.

Relation (β) between standardized LTL (y-axis) and age (x-axis) across three female reproductive life periods (red). Dotted vertical lines indicate mean age of first birth (26 years) and mean age at menopause (50 years). As a comparison, we depict the quadratic LTL regression in males (β_{age} ; β_{age^2} ; blue). 95% confidence intervals are shown for the linear predictions. Yellow background indicates the age range for which data is available (40-70 years) and used to build predictions; regions outside this range are extrapolated for males and estimated from age at first birth and age at menopause information for females.

246 Serum lipids

247 We found predominantly positive associations between LTL and serum lipid levels, i.e., apolipoprotein B (ApoB;
 248 $\beta = 0.019$; $p = 9.4e-25$), total cholesterol ($\beta = 0.019$; $p = 2.9e-27$), and LDL-cholesterol ($\beta = 0.022$; $p = 4.2e-35$)
 249 (Figure 2e). After adjusting for cholesterol-lowering drug use, the positive relation between LTL and both total and
 250 LDL-cholesterol decreased but remained significant (Figure S7b). LDL-cholesterol ($\alpha_{T \rightarrow LTL} = 0.036$; $p = 4.7e-10$)
 251 and ApoB ($\alpha_{T \rightarrow LTL} = 0.029$; $p = 2.6e-10$) levels also causally influenced LTL, which was corroborated by weighted
 252 mode MR, weighted median MR, and MR-Egger (Figure S3). Consistently, our findings suggest that disorders of
 253 lipid metabolism contribute to longer LTL ($\alpha_{T \rightarrow LTL} = 0.057$; $p = 1.4e-6$), reiterating the association between
 254 increased LTL and high serum lipid levels. Due to their correlated nature, MVMR including levels of LDL-cholesterol,
 255 ApoB, and triglycerides as exposures could not disentangle their individual contribution to LTL (Figure S6).

256 Renal health

257 Lasso analysis retained both urate ($\beta = -0.025$; $p = 2.1e-44$) and cystatin C ($\beta = -0.033$; $p = 2.2e-75$) levels as
 258 relevant predictors of LTL (Table 1), highlighting the link between kidney function and LTL. As previously reported
 259 [45], MR analyses showed that elevated urate levels decreased LTL ($\alpha_{T \rightarrow LTL} = -0.042$; $p = 9.4e-18$), possibly due
 260 to increased cellular stress and reactive oxygen species production [46]. The urate-LTL association was significantly

261 mediated by CRP, confirming the role of inflammation in this process ($P_M = 34.7\%$; 95%-CI[17.1%; 55.6%]). We also
262 found that shorter LTL increased the risk for chronic kidney disease (CKD; $\alpha_{LTL \rightarrow T} = -0.031$; $p = 1.5e-4$) (Figure
263 2f). Urate levels, which are frequently elevated in CKD patients [47], causally affected CKD risk ($\alpha = 0.034$; $p =$
264 $1.5e-8$) but this link was not mediated by LTL ($P_M = 4.5\%$; 95%-CI[-8.3%; 18.5%]) (Table S5).

265 Consequences of altered LTL

266 Blood cell counts

267 Hematological traits (e.g., white blood cell count: $\beta = -0.042$; $p = 2.9e-120$; and mean corpuscular hemoglobin
268 (MCH): $\beta = -0.054$; $p = 1.7e-200$) are among the ones showcasing the strongest observational correlation with
269 LTL (Figure 2g). For 4 out of 11 significantly correlated blood traits, we identified bidirectional causal relationships
270 with LTL, with less pronounced effects from traits on LTL (e.g., MCH: $\alpha_{LTL \rightarrow T} = -0.195$; $p = 2.2e-24$; $\alpha_{T \rightarrow LTL} =$
271 -0.034 ; $p = 5.2e-10$). While for MCH, eosinophil, platelet, and red blood cell counts, the effects from LTL on
272 the latter traits were robust across multiple MR methods (Figure S4), only white blood cell count ($\alpha_{T \rightarrow LTL} =$
273 -0.042 ; $p = 6.7e-9$) demonstrated a consistent effect on LTL (Figure S3). As telomere length was measured in
274 leukocytes, we cannot exclude that observed associations with blood traits are confounded by other factors, such as
275 blood cell counts. We therefore adjusted LTL for eosinophil, lymphocyte, monocyte, neutrophil, platelet, red blood
276 cell, reticulocyte, and white blood cell counts in addition to core covariates. Regressing this new variable on the
277 same 158 traits (i.e., 166 traits, excluding the 8 blood count traits we corrected for), we obtained highly similar effect
278 sizes ($\rho = 0.98$). Only associations with smoking status ($p_{diff.} = 1.4e-9$), smoking cessation ($p_{diff.} = 5.7e-6$), as
279 well as MCH ($p_{diff.} = 3.3e-26$) were significantly reduced, yet remained significant. Association with total bilirubin
280 ($p_{diff.} = 1.4e-5$) was lost, while the one with phosphate levels ($p_{diff.} = 8.0e-5$) became significant (Figure S8).

281 Hepatic biomarkers

282 LTL associated with levels of the hepatic biomarkers aspartate aminotransferase (AST; $\beta = -0.023$; $p = 1.6e-37$)
283 and albumin ($\beta = 0.007$; $p = 7.2e-5$) (Figure 2h). Accordingly, finding that shorter LTL causally associated with
284 higher AST ($\alpha_{LTL \rightarrow T} = -0.082$; $p = 3.7e-11$) and lower albumin levels ($\alpha_{LTL \rightarrow T} = 0.050$; $p = 9.1e-5$), telltales of
285 underlying liver or inflammatory conditions. Overall, these results underscore the potential role of telomere-driven
286 cellular aging in hepatic function deterioration and/or inflammatory processes.

287 Diseases

288 Short LTL correlated with increased risk for cardiovascular and pulmonary conditions, reflecting previous findings
289 [12, 48]. For instance, LTL had a negative causal impact on aneurysm risk ($\alpha_{LTL \rightarrow T} = -0.200$; $p = 1.2e-5$) and
290 a positive one on forced vital capacity ($\alpha_{LTL \rightarrow T} = 0.072$; $p = 3.2e-6$). In line with that, we observed a negative
291 correlation with risk for pulmonary diseases such as emphysema ($\beta = -0.013$; $p = 3.5e-12$) or chronic obstructive
292 pulmonary disease (COPD; $\beta = -0.025$; $p = 9.0e-40$). While the MR effects of LTL on emphysema ($\alpha_{LTL \rightarrow T} =$
293 -0.115 ; $p = 0.005$) or COPD ($\alpha_{LTL \rightarrow T} = -0.036$; $p = 0.014$) were concordant, they did not survive multiple testing
294 correction. In addition to replicating a previously established correlation between short LTL and increased risk for
295 ischemic heart disease ($\beta = -0.024$; $p = 6.6e-41$) [48], we also found causal evidence for the effect of LTL on
296 ischemic heart disease ($\alpha_{LTL \rightarrow T} = -0.061$; $p = 1.9e-09$). Hematological cancer risk negatively correlated with
297 LTL ($\beta = -0.015$; $p = 5.8e-14$), while longer LTL correlated with kidney ($\beta = 0.008$; $p = 9.4e-05$) and prostate
298 ($\beta = 0.029$; $p = 2.1e-23$) cancer risk. While we do not have causal estimates for the former, MR confirmed that
299 LTL causally increased risk for kidney ($\alpha_{LTL \rightarrow T} = 0.048$; $p = 8.1e-10$) and prostate ($\alpha_{LTL \rightarrow T} = 0.089$; $p = 1.0e-4$)
300 cancers (Figure 2k), aligning with previous findings [49, 17, 20, 50]. This paradox, in which both longer and shorter
301 LTL impact disease risk, was also observed in disorders with an autoimmune component, where shorter LTL is a risk
302 factor for rheumatoid arthritis ($\alpha_{LTL \rightarrow T} = -0.086$; $p = 9.2e-5$) and Alzheimer's disease ($\alpha_{LTL \rightarrow T} = -0.037$; $p =$
303 $1.3e-4$), while longer LTL increased risk for systemic lupus erythematosus ($\alpha_{LTL \rightarrow T} = 0.167$; $p = 5.8e-5$) (Figure
304 2l-o). Overall, these results highlight the disease-promoting role of both long and short LTL.

305 Mediating role of LTL

306 Analogously to DNA methylation, LTL represents a marker of biological age that can be viewed as a clock in-
307 tegrating a broad range of lifestyle and health parameters [51]. This raises the question whether LTL mediates
308 the relation between complex traits and lifespan. We tested the mediating role of LTL for the relation between
309 18 non-hematological LTL-modulating traits and lifespan, the latter being affected by LTL at nominal significance
310 ($\alpha_{LTL \rightarrow T} = 0.023$; $p = 0.006$). We identified five significant indirect effects ($p_{indirect} < 0.05/359$), i.e., mediated
311 through LTL (Figure 4a; Table S5). For instance, the negative impact of BMI ($P_M = 7.2\%$; 95%-CI[3.9%; 10.6%]) or
312 the positive effect of EA ($P_M = 18.8\%$; 95%-CI[12.3%; 25.7%]) on lifespan were partially mediated by LTL. Given the
313 considerable mediation of AFB ($P_M = 80.8\%$; 95%-CI[39.4%; 100%]) and ALB ($P_M = 100\%$; 95%-CI[70.1%; 100%]) on
314 lifespan by LTL, we further investigated these traits through an iterative MVMR approach to build a causal network
315 (Figure 4b; Table S3). Results emphasized the partial mediating role of LTL and EA on the effect of AFB on lifespan.

316

317 Given that lifestyle factors were found to affect LTL, which in turn influences risk for many diseases, we next used
318 MVMR to assess the LTL mediatory effect for all pairs of 18 LTL modulators and 19 LTL-affected traits. We identified
319 23 significant ($p_{indirect} < 0.05/359$) LTL-mediated relationships (Figure 4c; Table S5). Effects on ischemic heart
320 disease, total protein levels, and forced vital capacity were the most frequently mediated by LTL, whereas urate lev-
321 els, BMI, and EA were the most common exposures. Overall, while we do detect a substantial number of significant
322 mediations through LTL, the average mediation proportion is 5.45%, only accounting for a fraction of these relations.

323




Figure 4. Mediating role of LTL

a) Mediation analysis of 18 LTL-affecting exposures (y-axis; left) on lifespan (y-axis; right) through LTL with effect size estimates and 95% confidence intervals (CI; x-axis) of the total effect (i.e., IVW MR estimate of exposure on outcome; purple), direct effect (i.e., not mediated by LTL; MVMR estimate; pink) and indirect effect (i.e., LTL mediation by product method; orange) as displayed in the scheme in the bottom right corner of the figure. Displayed are relationships with significant ($p < 0.05/359$) total and indirect effects. b) Schematic illustration of the magnitude and direction of nominally significant MVMR effects ($p < 0.05$). Arrow thickness is proportional to the effect size. Significant effects from lifespan to EA are not displayed. c) Mediation analysis of 18 LTL-affecting exposures (y-axis; left) on 19 LTL-affected outcomes (y-axis; right) through LTL. Legend as in (a). EA = educational attainment; LDL = low-density lipoprotein; BMI = body mass index; IGF-1 = insulin-like growth factor 1; SHBG = sex hormone binding globulin; LTL = leukocyte telomere length.

324 Sex differences in LTL biology

325 Finally, we explored sex differences in LTL biology. We note that overall, there is high concordance between male
 326 and female effect estimates, which are highly correlated ($\rho = 0.92$; Figure 5). We sought to identify factors that could

327 explain the stronger age-related decline in LTL observed in males (Figure S1). Given that female reproductive events
328 seemed to impact the rate of telomere shortening in females (Figure 3), we explored whether hormonal effects
329 could account for this difference. Testosterone displayed a stronger association with LTL in males ($p_{\text{diff.}} = 4.8e-3$),
330 while sex hormone binding globulin (SHBG) was associated with LTL in males but not in females ($p_{\text{diff.}} = 2.2e-18$).
331 Correcting LTL for SHBG and testosterone in our sex-stratified regression with age did not abolish the sex difference
332 ($p_{\text{diff.}} = 1.3e-23$). Alternatively, lifestyle factors could account for part of the difference, given that beer consumption
333 ($p_{\text{diff.}} = 2.8e-6$) and smoking status ($p_{\text{diff.}} = 3.6e-3$) showed stronger negative associations with LTL in males, while
334 the association with fruit consumption was more pronounced in females ($p_{\text{diff.}} = 9.6e-4$). After correction for weekly
335 alcohol consumption, alcohol intake frequency, smoking status, as well as beef, vegetable, and fruit consumption,
336 the observed sex difference ($p_{\text{diff.}} = 1.0e-17$) was reduced but not in a significant way (Table S3). Other traits
337 showing a different association with LTL in males versus females include MCH ($p_{\text{diff.}} = 8.2e-12$) and IGF-1 ($p_{\text{diff.}} =$
338 $5.1e-8$) which were more strongly associated in males, while hip circumference was more strongly associated in
339 females ($p_{\text{diff.}} = 3.3e-4$). The association with aneurysm was male-specific ($p_{\text{diff.}} = 1.5e-4$), while urea levels
340 ($p_{\text{diff.}} = 1.0e-4$) exhibited a slight negative correlation in females and a positive one in males. Correcting LTL
341 for each of these traits and comparing sex-stratified regression with age did not account for observed differences.
342 Hence, the sex-specific LTL associations identified in our study do not appear to majorly contribute to sex differences
343 in LTL shortening.




Figure 5. Sex-specific phenome-wide LTL associations.

Female-specific (y-axis) against male-specific (x-axis) LTL-trait correlation estimates with 95% confidence intervals. Purple, pink, and smaller gray data points indicate traits with strictly significantly ($p_{diff.} < 0.05/141$), nominally significantly ($p_{diff.} < 0.05$), and non-significantly divergent estimates, respectively. Strictly significant traits are labeled in purple, while nominally significant lifestyles or hormonal traits are labeled in gray. Dashed grey and black lines represent the identity line and null effect sizes, respectively. Orange triangles in the top right corner denote non-significant differences in father's and mother's age at birth, which are beyond the plotting range (see Table S4).

344 Discussion

345 We comprehensively examined the bidirectional causal relationships between LTL and complex traits, diseases,
346 and lifestyle factors and used MVMR to examine causal effect mediation. Our study reiterates age and sex as major
347 determinants of LTL variability [41, 18] and while hormonal and lifestyle variations showed different associations
348 between males and females, they could not account for the observed sex differences. Still, the fact that lifestyle
349 factors causally affect LTL emphasizes their influence on aging at a physiological and molecular level. Furthermore,
350 we provide evidence for a causal role of abnormal LTL in a broad spectrum of clinically relevant traits, including can-
351 cer, autoimmune disorders, lung diseases, and cardiovascular conditions. Lastly, our results show that LTL partially
352 mediates the effect of BMI, EA, and reproductive traits on lifespan.

353

354 Others [20, 21] have also used MR to estimate the impact of LTL on 25 traits assessed in our study, all showing
355 concordant effects in our analyses. Notably, we identified a causal effect of LTL on CKD risk that was previously
356 missed, likely due to the reliance of these studies on UKBB summary statistics that were generated based on much
357 lower case counts than the consortia summary statistics used in our study. Earlier research suggested bidirectional
358 causality between telomere attrition and CKD [52]. While we replicated the deleterious impact of shorter LTL on
359 CKD risk, we did not find evidence for a reverse causal effect. Our study also supports the Alzheimer's disease
360 risk-increasing effect of shorter LTL [53, 54, 55, 56, 57] which was proposed to be driven by promotion of cellular
361 senescence. Paralleling a recent report [58], our results suggest that LTL variation increases the risk for some
362 autoimmune conditions, e.g., risk of systemic lupus erythematosus being increased by longer LTL. Overall, this
363 supports the deleterious role of both long and short telomeres in shaping human health.

364

365 Our study also estimated the causal effects of phenotypes on LTL. In line with prior research, alcohol consump-
366 tion [59], smoking [8, 60], obesity [61], and socioeconomic disadvantages [62] emerged as significant contributors
367 to telomere shortening, underscoring the potential benefits of lifestyle modifications. Some of these factors, such as
368 BMI and EA, were found to exert a small, albeit significant proportion of their impact on longevity through LTL. Sur-
369 prisingly, the positive influence of serum lipid levels on LTL often attenuated the total effect of lipid-trait relationships.
370 These results are unexpected as high cholesterol levels promote oxidative stress [63], which in turn accelerates LTL
371 shortening [64], warranting further studies to determine mechanisms through which higher lipid levels could favor
372 longer telomeres.

373

374 Lifestyle factors modulating LTL, such as alcohol intake, smoking, and dietary habits - which present with strong
375 sex differences and differentially impact LTL in males versus females - represent good candidates to explain the
376 increased rate of LTL shortening in males. Still, we could not demonstrate that these factors were responsible for
377 the differential rate of LTL shortening between sexes. These negative results might be driven by the fact that these
378 results rely on self-reported data that is inherently prone to reporting error [65] and thus represent imperfect proxies
379 of true behaviors, so that further investigations will be required to fully understand sex disparity in LTL shortening.
380 Importance in sex-specific LTL regulators is further highlighted by the finding that delayed AFB and ALB causally
381 associated with longer LTL, an association that was only partially confounded by SES. These results align with the
382 intensified LTL shortening rate we observed after childbirth, which further exacerbated post-menopause. Although
383 we did not observe an association between oestradiol levels - measured only in ~49,000 individuals - and LTL, we
384 hypothesize that hormonal shifts following pregnancy and menopause could accelerate LTL shortening [66]. An
385 alternative explanation is that LTL shortening is driven by the stress imposed by such events on the body. While
386 further research is required to test these hypotheses, our results highlight the prominent role of life history events in
387 LTL shortening rates. Overall, this emphasizes how hormonal and lifestyle factors can influence LTL, which in turn
388 impacts global health and disease risk through complex networks.

389

390 Our study is subject to several limitations. First, the use of cross-sectional bulk LTL limits our capacity to
391 analyze individual telomere shortening rates, which might be a critical factor in disease prediction [51]. Second,
392 although LTL and telomere length in other tissues are correlated [67], this proxy might miss more subtle and tissue-
393 specific relations between telomere length and the phenome. Furthermore, we cannot exclude that the tissue
394 in which telomere length was measured (i.e., leukocytes) biases the observed associations with hematological
395 traits, even if accounting for blood cell type traits did not seem to affect association estimates between LTL and
396 other traits. Third, our study focused on White-British ancestry, meaning the results may not necessarily apply
397 to other ethnicities. In the future, single-cell telomere length measured at chromosomal resolution through long-
398 read sequencing approaches across a wide variety of tissues, time points, and ancestral groups should provide a
399 more refined view of telomere dynamics. Fourth, MR presents with inherent restrictions, notably susceptibility to
400 horizontal pleiotropy violations, especially given the considerable heterogeneity across our IVs. In that optic, we
401 used a broad range of sensitivity analyses and focused on results robust across these various methods. Another
402 limitation of MR is that detection power is bound by the number of available IVs, so that our power to detect causal
403 relations between traits and LTL is variable across phenotypes and might be lower or larger than for the reverse LTL
404 on trait relation, depending on whether the trait has less or more IVs than LTL, respectively. Finally, MR does not

405 account for dynamic spatiotemporal changes in LTL that occur over lifetime and/or in the context of some diseases
406 such as cancer.

407 **Conclusion**

408 Through usage of univariable and multivariable bidirectional Mendelian randomization, we identify a complex net-
409 work of causal relations wherein both exogenous and endogenous environmental factors modulate LTL, which in
410 turn influences the risk for numerous diseases and mediates the impact of some of these traits on lifespan. Still,
411 based on currently available data, its mediatory role between unfavorable lifestyle and disease is estimated to be
412 modest, and further research is needed to explore the relation between LTL and other aging biomarkers, such as
413 DNA methylation, in order to understand its clinical value as a proxy of biological age.

Data and code Availability

All data used in this study are publicly available, as described in the methods. Code to reproduce analyses performed in this study is available at https://github.com/cChiiper/UNIL_SGG_MR_LTL

Acknowledgments

This research has been conducted using the UK Biobank Resource under Application Number 16389. We thank all UK biobank participants for sharing their data. Computations were performed on the JURA and Urblauna servers from the University of Lausanne. The study was funded by the Swiss National Science Foundation (310030_189147, ZK) and the Department of Computational Biology of the University of Lausanne (ZK).

Author contributions

SM, CA, and ZK conceived the study; SM carried out the analyses with contributions from MCS; ZK supervised statistical analyses; SM generated the figures; SM and CA drafted the manuscript and ZK made critical revisions; All authors read, approved, and provided feedback on the final manuscript.

Ethics declarations

The authors declare that they have no competing interests.

Supplementary information

Supplementary Information

Supplementary Note and Figures 1-9.

Supplementary Tables

Supplementary Tables 1-5.

References

- [1] Teresa Niccoli and Linda Partridge. Ageing as a risk factor for disease. *Current Biology*, 22(17):R741–R752, 2012. doi: 10.1016/j.cub.2012.07.024. URL <https://doi.org/10.1016/j.cub.2012.07.024>.
- [2] Lucas W. M. Diebel and Kenneth Rockwood. Determination of Biological Age: Geriatric Assessment vs Biological Biomarkers. *Current Oncology Reports*, 23(9):104–8, July 2021. ISSN 1534-6269. doi: 10.1007/s11912-021-01097-9.
- [3] Steve Horvath. Dna methylation age of human tissues and cell types. *Genome Biology*, 14(10):3156, 2013. doi: 10.1186/gb-2013-14-10-r115. URL <https://doi.org/10.1186/gb-2013-14-10-r115>.
- [4] Gregory Hannum, Justin Guinney, Li Zhao, Li Zhang, Gavin Hughes, Srinivas Sadda, Brandy Klotzle, Marina Bibikova, Jian-Bing Fan, Yang Gao, Rachel Deconde, Michael Chen, Indika Rajapakse, Stephen Friend, Trey Ideker, and Kun Zhang. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Molecular Cell*, 49(2):359–367, 2013. doi: 10.1016/j.molcel.2012.10.016. URL <https://doi.org/10.1016/j.molcel.2012.10.016>.
- [5] Yasmeen Salameh, Yosra Bejaoui, and Nady El Hajj. DNA Methylation Biomarkers in Aging and Age-Related Diseases. *Frontiers in Genetics*, 11:480672, March 2020. ISSN 1664-8021. doi: 10.3389/fgene.2020.00171.
- [6] Juulia Jylhävä, Nancy L. Pedersen, and Sara Hägg. Biological age predictors. *EBioMedicine*, 21:29–36, 2017. doi: 10.1016/j.ebiom.2017.03.046. URL <https://doi.org/10.1016/j.ebiom.2017.03.046>.
- [7] Masood A. Shammam. Telomeres, lifestyle, cancer, and aging. *Current Opinion in Clinical Nutrition & Metabolic Care*, 14(1):28, January 2011. ISSN 1363-1950. doi: 10.1097/MCO.0b013e32834121b1.
- [8] Yuliana Astuti, Ardan Wardhana, Johnathan Watkins, Wahyu Wulaningsih, and For the Pilar Research Network. Cigarette smoking and telomere length: A systematic review of 84 studies and meta-analysis. *Environmental Research*, 158:480, October 2017. doi: 10.1016/j.envres.2017.06.038.
- [9] Seonghyeok Song, Eunsang Lee, and Hyunjoong Kim. Does Exercise Affect Telomere Length? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicina*, 58(2), February 2022. doi: 10.3390/medicina58020242.
- [10] Ligi Paul. Diet, nutrition and telomere length. *Journal of Nutritional Biochemistry*, 22(10):895–901, October 2011. ISSN 0955-2863. doi: 10.1016/j.jnutbio.2010.12.001.
- [11] Nikolina Škrobot Vidaček, Lucia Nanić, Sanda Ravlić, Mary Sopta, Marko Gerić, Goran Gajski, Vera Garaj-Vrhovac, and Ivica Rubelj. Telomeres, Nutrition, and Longevity: Can We Really Navigate Our Aging? *Journals of Gerontology: Series A*, 73(1):39–47, January 2018. ISSN 1079-5006. doi: 10.1093/gerona/glx082.
- [12] Susan E. Stanley, Samantha J. Merck, and Mary Armanios. Telomerase and the Genetics of Emphysema Susceptibility. Implications for Pathogenesis Paradigms and Patient Care. *Annals of the American Thoracic Society*, 13(Suppl 5):S447, December 2016. doi: 10.1513/AnnalsATS.201609-718AW.
- [13] Oluwatoyin I. Ameh, Ikechi G. Okpechi, Collet Dandara, and André-Pascal Kengne. Association Between Telomere Length, Chronic Kidney Disease, and Renal Traits: A Systematic Review. *OMICS: A Journal of Integrative Biology*, 21(3):143–155, March 2017. doi: 10.1089/omi.2016.0180.
- [14] Francesca Rossiello, Diana Jurk, João F. Passos, and Fabrizio D'Adda di Fagnana. Telomere dysfunction in ageing and age-related diseases. *Nature Cell Biology*, 24(2):135–147, February 2022. ISSN 1476-4679. doi: 10.1038/s41556-022-00842-x.
- [15] John Maciejowski and Titia de Lange. Telomeres in cancer: tumour suppression and genome instability. *Nature Reviews Molecular Cell Biology*, 18(3):175–186, March 2017. ISSN 1471-0080. doi: 10.1038/nrm.2016.171.
- [16] Jia-Min Zhang and Lee Zou. Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks. *Cell & Bioscience*, 10(1):1–9, December 2020. ISSN 2045-3701. doi: 10.1186/s13578-020-00391-6.
- [17] Abraham Aviv, James J. Anderson, and Jerry W. Shay. Mutations, Cancer and the Telomere Length Paradox. *Trends in Cancer*, 3(4):253–258, April 2017. ISSN 2405-8033. doi: 10.1016/j.trecan.2017.02.005.
- [18] Patrick Allaire, Jing He, John Mayer, Luke Moat, Peter Gerstenberger, Reynor Wilhorn, Sierra Strutz, David S. L. Kim, Chenjie Zeng, Nancy Cox, Jerry W. Shay, Joshua Denny, Lisa Bastarache, and Scott Hebring. Genetic and clinical determinants of telomere length. *Human Genetics and Genomics Advances*, 4(3), July 2023. ISSN 2666-2477. doi: 10.1016/j.xhgg.2023.100201.
- [19] Veryan Codd, Matthew Denniff, Charlotte Swinfield, Sophie C. Warner, Maria Papakonstantinou, Sheetal Sheth, David E. Nanus, Claire A. Budgeon, Crispin Musicha, Vasiliki Bountziouka, Qiaoji Wang, Rachel Bramley, Elias Allara, Stephen Kaptoge, Simeon Stoma, Tao Jiang, Adam S. Butterworth, Angela M. Wood, Emanuele Di Angelantonio, and Nilesh J. Samani. Measurement and initial characterization of leukocyte telomere length in 474,074 participants in uk biobank. *Nature Aging*, 2(2):170–179, 2022. doi: 10.1038/s43587-021-00166-9. URL <https://doi.org/10.1038/s43587-021-00166-9>.
- [20] Veryan Codd, Qingning Wang, Elias Allara, Crispin Musicha, Stephen Kaptoge, Svetlana Stoma, Tao Jiang, Stephen E. Hamby, Peter S. Braund, Vasiliki Bountziouka, Charley A. Budgeon, Matthew Denniff, Chloe Swinfield, Manolo Papakonstantinou, Shilpi Sheth, Dominika E. Nanus, Sophie C. Warner, Minxian Wang, Amit V. Khera, James Eales, Willem H. Ouweland, John R. Thompson, Emanuele Di Angelantonio, Angela M. Wood, Adam S. Butterworth, John N. Danesh, Christopher P. Nelson, and Nilesh J. Samani. Polygenic basis and biomedical consequences of telomere length variation. *Nature Genetics*, 53(10):1425–1433, October 2021. ISSN 1546-1718. doi: 10.1038/s41588-021-00944-6.

- [21] Wenxiu Wang, Ninghao Huang, Zhenhuang Zhuang, Zimin Song, Yueying Li, Xue Dong, Wendi Xiao, Yimin Zhao, Jinzhu Jia, Zhonghua Liu, et al. Identifying Potential Causal Effects of Telomere Length on Health Outcomes: A Phenome-Wide Investigation and Mendelian Randomization Study. *Journals of Gerontology: Series A*, page glad128, May 2023. ISSN 1758-535X. doi: 10.1093/gerona/glad128.
- [22] Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T. Elliott, Kevin Sharp, Allan Motyer, Damjan Vukcevic, Olivier Delaneau, Jared O'Connell, Adrian Cortes, Samantha Welsh, Alan Young, Mark Effingham, Gil McVean, Stephen Leslie, Naomi Allen, Peter Donnelly, and Jonathan Marchini. The UK Biobank resource with deep phenotyping and genomic data. *Nature*, 562(7726):203–209, October 2018. ISSN 1476-4687. doi: 10.1038/s41586-018-0579-z.
- [23] Patrick Wu, Aliya Gifford, Xiangrui Meng, Xue Li, Harry Campbell, Tim Varley, Juan Zhao, Robert Carroll, Lisa Bastarache, Joshua C. Denny, Evropi Theodoratou, and Wei-Qi Wei. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. *JMIR Medical Informatics*, 7(4):e14325, November 2019. doi: 10.2196/14325.
- [24] Chiara Auwerx, Maarja Jõeloo, Marie C. Sadler, Nicolò Tesio, Sven Ojavee, Charlie J. Clark, Reedik Mägi, Estonian Biobank Research Team, Alexandre Reymond, and Zoltán Kutalik. Copy-number variants as modulators of common disease susceptibility. *medRxiv*, page 2023.07.31.23293408, August 2023. URL <https://doi.org/10.1101/2023.07.31.23293408>.
- [25] Xiaoyi Gao, Joshua Starmer, and Eden R. Martin. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genetic Epidemiology*, 32(4):361–369, May 2008. ISSN 0741-0395. doi: 10.1002/gepi.20310.
- [26] Marie C. Sadler, Chiara Auwerx, Patrick Deelen, and Zoltán Kutalik. Multi-layered genetic approaches to identify approved drug targets. *Cell Genomics*, 3(7):100341, July 2023. ISSN 2666-979X. doi: 10.1016/j.xgen.2023.100341.
- [27] The UK10K Consortium. The uk10k project identifies rare variants in health and disease. *Nature*, 526(7571):82–90, October 2015. ISSN 1476-4687. doi: 10.1038/nature14962.
- [28] Marie C. Sadler, Chiara Auwerx, Kaido Lepik, Eleonora Porcu, and Zoltán Kutalik. Quantifying the role of transcript levels in mediating DNA methylation effects on complex traits and diseases. *Nat. Commun.*, 13(7559):1–14, December 2022. ISSN 2041-1723. doi: 10.1038/s41467-022-35196-3.
- [29] Jerome H. Friedman, Trevor Hastie, and Robert Tibshirani. Regularization paths for generalized linear models via coordinate descent. *Journal of Statistical Software*, 33(1):1–22, 2010. doi: 10.18637/jss.v033.i01.
- [30] Jayne E. Edwards and R. Andrew Moore. Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. *BMC Fam. Pract.*, 4(1):1–19, December 2003. ISSN 1471-2296. doi: 10.1186/1471-2296-4-18.
- [31] Christopher C. Chang, Carson C. Chow, Laurent Cam Tellier, Shashaank Vattikuti, Shaun M. Purcell, and James J. Lee. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*, 4(1):13742–015, December 2015. ISSN 2047-217X. doi: 10.1186/s13742-015-0047-8.
- [32] Adriaan van der Graaf, Maria M. Zorro, Anniëke Claringboud, Urmo Vösa, Raúl Aguirre-Gamboa, Chan Li, Joram Mooiweer, Isis Ricaño-Ponce, Zuzanna Borek, Frits Koning, Yvonne Kooy-Winkelaar, Ludvig M. Sollid, Shuo-Wang Qiao, Vinod Kumar, Yang Li, Lude Franke, Sebo Withoff, Cisca Wijmenga, Serena Sanna, Iris Jonkers, and BIOS Consortium. Systematic Prioritization of Candidate Genes in Disease Loci Identifies TRAFD1 as a Master Regulator of IFN γ Signaling in Celiac Disease. *Frontiers in Genetics*, 11:562434, January 2021. ISSN 1664-8021. doi: 10.3389/fgene.2020.562434.
- [33] Gibran Hemani, Jie Zheng, Benjamin Elsworth, Kaitlin H. Wade, Valeria Haberland, Denis Baird, Charles Laurin, Stephen Burgess, Jack Bowden, Ryan Langdon, Vanessa Y. Tan, James Yarmolinsky, Hashem A. Shihab, Nicholas J. Timpson, David M. Evans, Caroline Relton, Richard M. Martin, George Davey Smith, Tom R. Gaunt, and Philip C. Haycock. The MR-Base platform supports systematic causal inference across the human phenome. *eLife*, May 2018. doi: 10.7554/eLife.34408.
- [34] Marie Verbanck, Chia-Yen Chen, Benjamin Neale, and Ron Do. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nature Genetics*, 50(5):693–698, May 2018. ISSN 1546-1718. doi: 10.1038/s41588-018-0099-7.
- [35] Eleanor Sanderson, M. Maria Glymour, Michael V. Holmes, Hyunseung Kang, Jean Morrison, Marcus R. Munafò, Tom Palmer, C. Mary Schooling, Chris Wallace, Qingyuan Zhao, et al. Mendelian randomization. *Nature Reviews Methods Primers*, 2(6):1–21, February 2022. ISSN 2662-8449. doi: 10.1038/s43586-021-00092-5.
- [36] Paul Rhj Timmers, Ninon Mounier, Kristi Lall, Krista Fischer, Zheng Ning, Xiao Feng, Andrew D. Bretherick, David W. Clark, eQTLGen Consortium, Xia Shen, Tõnu Esko, Zoltán Kutalik, James F. Wilson, and Peter K. Joshi. Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. *eLife*, January 2019. doi: 10.7554/eLife.39856.
- [37] Alice R. Carter, Eleanor Sanderson, Gemma Hammerton, Rebecca C. Richmond, George Davey Smith, Jon Heron, Amy E. Taylor, Neil M. Davies, and Laura D. Howe. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. *European Journal of Epidemiology*, 36(5):465–478, May 2021. ISSN 1573-7284. doi: 10.1007/s10654-021-00757-1.
- [38] Jonathan Sulc, Anthony Sonrel, Ninon Mounier, Chiara Auwerx, Eirini Marouli, Liza Darrous, Bogdan Draganski, Tuomas O. Kilpeläinen, Peter Joshi, Ruth J. F. Loos, and Zoltán Kutalik. Composite trait Mendelian randomization reveals distinct metabolic and lifestyle consequences of differences in body shape. *Communications Biology*, 4(1064):1–13, September 2021. ISSN 2399-3642. doi: 10.1038/s42003-021-02550-y.
- [39] Eleanor Sanderson, Wes Spiller, and Jack Bowden. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Statistics in Medicine*, 40(25):5434–5452, November 2021. ISSN 0277-6715. doi: 10.1002/sim.9133.
- [40] Jack Bowden, Gibran Hemani, and George Davey Smith. Invited Commentary: Detecting Individual and Global Horizontal Pleiotropy in Mendelian Randomization—A Job for the Humble Heterogeneity Statistic? *American Journal of Epidemiology*, 187(12):2681–2685, December 2018. ISSN 0002-9262. doi: 10.1093/aje/kwy185.
- [41] Michael Gardner, David Bann, Laura Wiley, Rachel Cooper, Rebecca Hardy, Dorothea Nitsch, Carmen Martin-Ruiz, Paul Shiels, Avan Aihie Sayer, Michelangelo Barbieri, Sofie Bekaert, Claus Bischoff, Angela Brooks-Wilson, Wei Chen, Cyrus Cooper, Kaare Christensen, Tim De Meyer, Ian Deary, Geoff Der, Ana Diez Roux, Annette Fitzpatrick, Anjum Hajat, Julius Halaschek-Wiener, Sarah Harris, Steven C. Hunt, Carol Jagger, Hyo-Sung Jeon, Robert Kaplan, Masayuki Kimura, Peter Landsorp, Changyong Li, Toyoki Maeda, Massimo Mangino, Tim S. Nawrot, Peter Nilsson, Katarina Nordfjäll, Giuseppe Paolesso, Fu Ren, Karl Riabowol, Tony Robertson, Goran Roos, Jan A. Staessen, Tim Spector, Nelson Tang, Brad Unryn, Pim van der Harst, Jean Woo, Chao Xing, Mohammad E. Yadegarfar, Jae Yong Park, Neal Young, Diana Kuh, Thomas von Zglinicki, and Yoav Ben-Shlomo. Gender and telomere length: Systematic review and meta-analysis. *Experimental Gerontology*, 51:15–27, March 2014. ISSN 0531-5565. doi: 10.1016/j.exger.2013.12.004.
- [42] Pamela E. Davis-Kean, Lauren A. Tighe, and Nicholas E. Waters. The Role of Parent Educational Attainment in Parenting and Children's Development. *Current Directions in Psychological Science*, 30(2):186–192, April 2021. ISSN 0963-7214. doi: 10.1177/09637214211993116.
- [43] Samuel R. Chamberlain, Jonathan Cavanagh, Peter de Boer, Valeria Mondelli, Declan N. C. Jones, Wayne C. Drevets, Philip J. Cowen, Neil A. Harrison, Linda Parnell, Carmine M. Pariante, et al. Treatment-resistant depression and peripheral C-reactive protein. *British Journal of Psychiatry*, 214(1):11–19, January 2019. ISSN 0007-1250. doi: 10.1192/bjp.2018.66.
- [44] Pedro A. Pousa, Raquel M. Souza, Paulo Henrique M. Melo, Bernardo H. M. Correa, Tamires S. C. Mendonça, Ana Cristina Simões-e. Silva, and Débora M. Miranda. Telomere Shortening and Psychiatric Disorders: A Systematic Review. *Cells*, 10(6):1423, June 2021. ISSN 2073-4409. doi: 10.3390/cells10061423.
- [45] Zhengtao Lv, Jiarui Cui, and Jiaming Zhang. Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort. *Frontiers in Immunology*, 13:1065739, December 2022. ISSN 1664-3224. doi: 10.3389/fimmu.2022.1065739.
- [46] Masafumi Kurajoh, Shinya Fukumoto, Shio Yoshida, Seigo Akari, Takayo Murase, Takashi Nakamura, Haruka Ishii, Hisako Yoshida, Yuki Nagata, Tomoaki Morioka, et al. Uracil acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry. *Scientific Reports*, 11(7378):1–9, April 2021. ISSN 2045-2322. doi: 10.1038/s41598-021-86962-0.

- [47] Richard J. Johnson, Laura G. Sanchez Lozada, Miguel A. Lanaspá, Federica Piani, and Claudio Borghi. Uric Acid and Chronic Kidney Disease: Still More to Do. *Kidney International Reports*, 8(2):229–239, February 2023. ISSN 2468-0249. doi: 10.1016/j.ekir.2022.11.016.
- [48] Alexander Scheller Madrid, Line Rode, Børge G. Nordestgaard, and Stig E. Bojesen. Short Telomere Length and Ischemic Heart Disease: Observational and Genetic Studies in 290 022 Individuals. *Clinical Chemistry*, 62(8):1140–1149, August 2016. ISSN 0009-9147. doi: 10.1373/clinchem.2016.258566.
- [49] Line Rode, Børge G. Nordestgaard, and Stig E. Bojesen. Long telomeres and cancer risk among 95 568 individuals from the general population. *International Journal of Epidemiology*, 45(5):1634–1643, October 2016. ISSN 0300-5771. doi: 10.1093/ije/dyw179.
- [50] Bangbei Wan, Likui Lu, and Cai Lv. Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer. *PLOS ONE*, 18(6):e0286219, June 2023. ISSN 1932-6203. doi: 10.1371/journal.pone.0286219.
- [51] Alexander Vaiserman and Dmytro Krasniukov. Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and Future Perspectives. *Frontiers in Genetics*, 11:630186, January 2021. ISSN 1664-8021. doi: 10.3389/fgene.2020.630186.
- [52] Sehoon Park, Soojin Lee, Yaerim Kim, Semin Cho, Kwangsoo Kim, Yong Chul Kim, Seung Seok Han, Hajeong Lee, Jung Pyo Lee, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, and Dong Ki Kim. A Mendelian randomization study found causal linkage between telomere attrition and chronic kidney disease. *Kidney International*, 100(5):1063–1070, November 2021. ISSN 0085-2538. doi: 10.1016/j.kint.2021.06.041.
- [53] Zhiyou Cai, Liang-Jun Yan, and Anna Ratka. Telomere Shortening and Alzheimer’s Disease. *NeuroMolecular Medicine*, 15(1):25–48, March 2013. ISSN 1559-1174. doi: 10.1007/s12017-012-8207-9.
- [54] Tina Levstek, Eva Kozjek, Vita Dolžan, and Katarina Trebušak Podkrajšek. Telomere Attrition in Neurodegenerative Disorders. *Frontiers in Cellular Neuroscience*, 14:556488, July 2020. ISSN 1662-5102. doi: 10.3389/fncel.2020.00219.
- [55] Lana Fani, Saima Hilal, Sanaz Sedaghat, Linda Broer, Silvan Licher, Pascal P. Arp, Joyce B. J. van Meurs, M. Kamran Ikram, and M. Arfan Ikram. Telomere Length and the Risk of Alzheimer’s Disease: The Rotterdam Study. *Journal of Alzheimer’s Disease*, 73(2):707–714, January 2020. ISSN 1387-2877. doi: 10.3233/JAD-190759.
- [56] Fernanda Schäfer Hackenhaar, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman, and Sara Pudas. Short leukocyte telomeres predict 25-year Alzheimer’s disease incidence in non-APOE ϵ 4-carriers. *Alzheimer’s Research & Therapy*, 13(1):1–13, December 2021. ISSN 1758-9193. doi: 10.1186/s13195-021-00871-y.
- [57] Guangping Yu, Leihong Lu, Zaihong Ma, and Shouhai Wu. Genetically Predicted Telomere Length and Its Relationship With Alzheimer’s Disease. *Frontiers in Genetics*, 12:595864, February 2021. ISSN 1664-8021. doi: 10.3389/fgene.2021.595864.
- [58] Meiling Liu, Ping Luo, Lihua Liu, Xianping Wei, Xue Bai, Jicui Li, Linlin Wu, and Manyu Luo. Immune-mediated inflammatory diseases and leukocyte telomere length: A Mendelian randomization study. *Frontiers in Genetics*, 14:1129247, April 2023. ISSN 1664-8021. doi: 10.3389/fgene.2023.1129247.
- [59] A. Topiwala, B. Taschler, K. P. Ebmeier, S. Smith, H. Zhou, D. F. Levey, V. Codd, N. J. Samani, J. Gelernter, T. E. Nichols, et al. Alcohol consumption and telomere length: Mendelian randomization clarifies alcohol’s effects. *Molecular Psychiatry*, 27(10):4001–4008, October 2022. ISSN 1476-5578. doi: 10.1038/s41380-022-01690-9.
- [60] Sehoon Park, Seong Geun Kim, Soojin Lee, Yaerim Kim, Semin Cho, Kwangsoo Kim, Yong Chul Kim, Seung Seok Han, Hajeong Lee, Jung Pyo Lee, et al. Causal linkage of tobacco smoking with ageing: Mendelian randomization analysis towards telomere attrition and sarcopenia. *Journal of Cachexia, Sarcopenia and Muscle*, 14(2):955–963, April 2023. ISSN 2190-5991. doi: 10.1002/jcsm.13174.
- [61] Bangbei Wan, Ning Ma, and Cai Lv. Identifying effects of genetic obesity exposure on leukocyte telomere length using Mendelian randomization. *PeerJ*, 11:e15085, March 2023. ISSN 2167-8359. doi: 10.7717/peerj.15085.
- [62] Belinda L. Needham, Bilinda Straight, Charles E. Hilton, Charles Owuor Olungah, and Jue Lin. Family socioeconomic status and child telomere length among the Samburu of Kenya. *Social Science & Medicine*, 283:114182, August 2021. ISSN 0277-9536. doi: 10.1016/j.socscimed.2021.114182.
- [63] Einat Rauchbach, Haim Zeigerman, Diana Abu-Halaka, and Oren Tirosh. Cholesterol Induces Oxidative Stress, Mitochondrial Damage and Death in Hepatic Stellate Cells to Mitigate Liver Fibrosis in Mice Model of NASH. *Antioxidants*, 11(3):536, March 2022. ISSN 2076-3921. doi: 10.3390/antiox11030536.
- [64] Thomas von Zglinicki. Oxidative stress shortens telomeres. *Trends in Biochemical Sciences*, 27(7):339–344, July 2002. ISSN 0968-0004. doi: 10.1016/S0968-0004(02)02110-2.
- [65] Tabea Schoeler, Jean-Baptiste Pingault, and Zoltán Kutalik. Self-report inaccuracy in the UK Biobank: Impact on inference and interplay with selective participation. *medRxiv*, page 2023.10.06.23296652, October 2023. URL <https://doi.org/10.1101/2023.10.06.23296652>.
- [66] Abraham Aviv, Jerry Shay, Karre Christensen, and Woodruff Wright. The Longevity Gender Gap: Are Telomeres the Explanation? *Science of Aging Knowledge Environment*, 2005(23):pe16, June 2005. ISSN 1539-6150. doi: 10.1126/sageke.2005.23.pe16.
- [67] Kathryn Demanelis, Farzana Jasmine, Lin S. Chen, Meytal Chernoff, Lin Tong, Dayana Delgado, Chenan Zhang, Justin Shinkle, Mekala Sabarinathan, Hannah Lin, et al. Determinants of telomere length across human tissues. *Science (New York, N.Y.)*, 369(6509):eaaz6876., September 2020. ISSN 1095-9203. doi: 10.1126/science.aaz6876.